Nandrolone Decanoate is indicated for the treatment of established osteoporosis, disseminated breast cancer in women (as palliative therapy), protein deficiency following major surgery or trauma, anemia associated with chronic renal failure, aplastic anemia, anemia induced by cytotoxic therapy, chronic debilitating conditions in the elderly, post-operative and post-traumatic catabolic states, and during glucocorticosteroid therapy.

Nandrolone Decanoate is an injectable anabolic agent containing nandrolone as its active ingredient. The decanoate ester allows a sustained release, providing a duration of action of approximately three weeks after administration. It is structurally related to testosterone but exhibits greater anabolic activity with comparatively lower androgenic effects, as demonstrated in experimental and clinical studies.

In humans, it enhances calcium metabolism and contributes to increased bone mass in osteoporosis. In cases of advanced breast cancer in women, it may result in measurable tumor regression lasting several months. Additionally, it exerts a nitrogen-retaining effect that supports protein metabolism. This property is beneficial in managing protein deficiency conditions such as chronic debilitating diseases, and during recovery from major surgery or severe trauma. In such situations, it acts as an adjunct to primary treatment, nutritional support, and parenteral therapy.

At recommended doses, androgenic side effects (such as virilization) are relatively uncommon. It does not contain the C17-alpha alkyl group, which is typically linked to liver dysfunction and cholestasis.

• Established Osteoporosis: 50 mg every 3 weeks
• Disseminated breast cancer in women (palliative therapy): 50 mg every 3 weeks
• Protein deficiency states occurring after major surgery or trauma: 50 mg every 2–3 weeks
• Anemia due to chronic renal failure: 50–200 mg per week
• Aplastic anemia: 50–150 mg per week
• Anemia due to cytotoxic therapy: 200 mg per week
• Chronic debilitating disease in elderly: 100 mg
• Postsurgical and post-traumatic catabolism: 25–50 mg every 3 weeks
• During glucocorticosteroid therapy: 50 mg every 2–3 week

Should be administered by deep intramuscular injection. For an optimal therapeutic effect it is necessary to administer adequate amounts of vitamins, minerals and protein in a calorie-rich diet.

Nandrolone Decanoate Due to its long-acting nature, adverse effects may not subside immediately after discontinuation. Injectable preparations may also cause local reactions at the injection site. Depending on the dose, frequency, and duration of use, possible side effects include: virilism, hyperlipidaemia, increased libido, hypertension, dysphonia, nausea, abnormal liver function, peliosis hepatis, acne, rash, pruritus, hirsutism, premature epiphyseal closure, reduced urine flow, benign prostatic hyperplasia, priapism, enlargement of penis or clitoris, amenorrhoea, oligomenorrhoea, decreased sperm count, oedema, injection site reactions, decreased HDL, and increased haemoglobin.

Nandrolone Decanoate is contraindicated in pregnancy, male breast carcinoma, prostatic carcinoma, and in patients with hypersensitivity to peanuts, soya, or any component of the formulation including arachis oil.

Nandrolone Decanoate is contraindicated during pregnancy due to the risk of masculinization of the fetus. There is insufficient evidence regarding its safety during breastfeeding; potential risks to the infant or effects on milk production cannot be ruled out.

Nandrolone Decanoate If signs of virilisation develop, discontinuation of treatment should be considered, preferably in consultation with the patient.

It is recommended to monitor patients with any of the following conditions:

• latent or overt cardiac failure, renal dysfunction, hypertension or migraine (or history of these conditions), since anabolic steroids may occasionally cause fluid retention.
• In patients with incomplete statural growth, high doses may accelerate epiphyseal closure. In skeletal metastases of breast carcinoma, hypercalcaemia may develop either spontaneously or as a result of anabolic steroid therapy.
• This may indicate a positive tumour response to hormonal treatment. However, hypercalcaemia should first be treated appropriately, and hormone therapy may be resumed after normalization of calcium levels.
• Caution is advised in patients with liver dysfunction.

The use of anabolic steroids to enhance athletic performance may carry severe health risks and should be strongly discouraged.

Nandrolone Decanoate shows very low acute toxicity in animal studies. There are no well-documented reports of acute overdose in humans.

Nandrolone Decanoate Anabolic steroid (androgen), hormone that supports bone formation.

Nandrolone Decanoate Store below 30°C, protected from light and moisture. Keep out of reach of children.